The primary purpose of this requirement is to acquire a hazard and risk assessment protocol that requires special consideration to include 1) unique biological characteristics which may have an impact…
Ended Purchase Order Awarded Last action
- Contract number
- 75F40121P00501
- Awardee
-
Toxstrategies, LLC UEI FKS1YHGM3AN9
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $428,940
Award facts
- Contract value 100% obligated
- $428,940.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Austin, TX 78759, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $173,390 | |
| Supplemental Agreement for work within scope | $50,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $205,550 |
About this award
This is a $428,940.00 firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Toxstrategies, LLC, a small business based in Austin, Texas. The primary purpose of the contract is to acquire a hazard and risk assessment protocol that requires special consideration for unique biological characteristics that may impact the evaluation of ingredients in cosmetic products. This contract has a total small business set-aside designation. Toxstrategies is a multidisciplinary scientific consulting firm with expertise in toxicology and related services. The company has previously supported federal agencies, including the FDA, through technical guidance, chemical and product assessments, and consulting services for drug development, regulation, and litigation.
Description
The primary purpose of this requirement is to acquire a hazard and risk assessment protocol that requires special consideration to include 1) unique biological characteristics which may have an impact in the evaluation of ingredients in cosmetic
Quick answers
Who was awarded contract 75F40121P00501?
75F40121P00501 was awarded to Toxstrategies, LLC by Food and Drug Administration (Department of Health and Human Services) on September 2, 2021.
How much is contract 75F40121P00501 worth?
The government has obligated $428,940 on 75F40121P00501.
Was contract 75F40121P00501 competed?
The extent of competition for 75F40121P00501 was competed under sap. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award